Download PDF
CC BY 4.0 · Indian Journal of Neurosurgery 2023; 12(02): 097-103
DOI: 10.1055/s-0043-1770910
Review Article

Molecular Imaging of Glial Tumors: Established and Emerging Tracers

Indraja D. Dev 
1   Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Venkatesh Rangarajan
1   Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Nilendu C. Purandare
1   Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Ameya D. Puranik 
1   Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Various positron emission tomography (PET) tracers have been developed and extensively studied in the field of neuro-oncology imaging. In the management of brain tumors, accurate delineation of tumor extent, assessment of treatment response, and detection of early recurrence are the most important factors. At present, conventional anatomical imaging paired with amino acid tracer PET imaging is the recommended imaging modality for glial tumor evaluation. Newer PET tracers targeting various structures in the tumor microenvironment have been extensively studied. This review summarizes the established and emerging PET tracers having potential impact on neuro-oncology practice.

Keywords

FDG - FET - FDOPA - PET/CT - glioma


Publication History

Article published online:
24 July 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ShU. glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 2017; 18 (01) 3-9
    CrossrefPubMedGoogle Scholar
  • 2 Liang J, Lv X, Lu C. et al. Prognostic factors of patients with gliomas - an analysis on 335 patients with glioblastoma and other forms of gliomas. BMC Cancer 2020; 20 (01) 35
    CrossrefPubMedGoogle Scholar
  • 3 Strauss SB, Meng A, Ebani EJ, Chiang GC. Imaging glioblastoma posttreatment: progression, pseudoprogression, pseudoresponse, radiation necrosis. Radiol Clin North Am 2019; 57 (06) 1199-1216
    CrossrefPubMedGoogle Scholar
  • 4 Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010; 9 (09) 906-920
    CrossrefPubMedGoogle Scholar
  • 5 Kumar AJ, Leeds NE, Fuller GN. et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000; 217 (02) 377-384
    CrossrefPubMedGoogle Scholar
  • 6 Ahluwalia MS, Wen PY. Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. Expert Rev Anticancer Ther 2011; 11 (05) 653-656
    CrossrefPubMedGoogle Scholar
  • 7 Wen PY, Macdonald DR, Reardon DA. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28 (11) 1963-1972
    CrossrefPubMedGoogle Scholar
  • 8 Werner JM, Lohmann P, Fink GR, Langen KJ, Galldiks N. Current landscape and emerging fields of PET imaging in patients with brain tumors. Molecules 2020; 25 (06) 1471
    CrossrefPubMedGoogle Scholar
  • 9 Albert NL, Weller M, Suchorska B. et al. Response assessment in neuro-oncology working group and European Association for Neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-oncol 2016; 18 (09) 1199-1208
    CrossrefPubMedGoogle Scholar
  • 10 Almuhaideb A, Papathanasiou N, Bomanji J. 18F-FDG PET/CT imaging in oncology. Ann Saudi Med 2011; 31 (01) 3-13
    CrossrefPubMedGoogle Scholar
  • 11 Kawada K, Iwamoto M, Sakai Y. Mechanisms underlying 18F-fluorodeoxyglucose accumulation in colorectal cancer. World J Radiol 2016; 8 (11) 880-886
    CrossrefPubMedGoogle Scholar
  • 12 Rahman WT, Wale DJ, Viglianti BL. et al. The impact of infection and inflammation in oncologic 18F-FDG PET/CT imaging. Biomed Pharmacother 2019; 117: 109168
    CrossrefPubMedGoogle Scholar
  • 13 Galldiks N, Langen KJ, Albert NL. et al. PET imaging in patients with brain metastasis-report of the RANO/PET group. Neuro-oncol 2019; 21 (05) 585-595
    CrossrefPubMedGoogle Scholar
  • 14 Gupta M, Gupta T, Purandare N. et al. Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma. CNS Oncol 2019; 8 (04) CNS46
    CrossrefPubMedGoogle Scholar
  • 15 Gupta T, Manjali JJ, Kannan S, Purandare N, Rangarajan V. Diagnostic performance of pretreatment 18F-fluorodeoxyglucose positron emission tomography with or without computed tomography in patients with primary central nervous system lymphoma: updated systematic review and diagnostic test accuracy meta-analyses. Clin Lymphoma Myeloma Leuk 2021; 21 (08) 497-507
    CrossrefPubMedGoogle Scholar
  • 16 Zou Y, Tong J, Leng H, Jiang J, Pan M, Chen Z. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: a systematic review and meta-analysis. Oncotarget 2017; 8 (25) 41518-41528
    CrossrefPubMedGoogle Scholar
  • 17 Purandare NC, Puranik A, Shah S. et al. Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation?. Nucl Med Commun 2017; 38 (12) 1109-1116
    CrossrefPubMedGoogle Scholar
  • 18 Dankbaar JW, Snijders TJ, Robe PA. et al. The use of (18)F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma. J Neurooncol 2015; 125 (01) 167-175
    CrossrefPubMedGoogle Scholar
  • 19 Dev ID, Puranik AD, Purandare NC. et al. Prognostic significance of 18F-FDG PET/CT parameters in IDH-1 wild-type GBM and correlation with molecular markers. Nucl Med Commun 2021; 42 (11) 1233-1238
    CrossrefPubMedGoogle Scholar
  • 20 Patronas NJ, Di Chiro G, Kufta C. et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985; 62 (06) 816-822
    CrossrefPubMedGoogle Scholar
  • 21 Langen KJ, Galldiks N, Hattingen E, Shah NJ. Advances in neuro-oncology imaging. Nat Rev Neurol 2017; 13 (05) 279-289
    CrossrefPubMedGoogle Scholar
  • 22 Youland RS, Kitange GJ, Peterson TE. et al. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol 2013; 111 (01) 11-18
    CrossrefPubMedGoogle Scholar
  • 23 Papin-Michault C, Bonnetaud C, Dufour M. et al. Study of LAT1 expression in brain metastases: towards a better understanding of the results of positron emission tomography using amino acid tracers. PLoS One 2016; 11 (06) e0157139
    CrossrefPubMedGoogle Scholar
  • 24 Wiriyasermkul P, Nagamori S, Tominaga H. et al. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med 2012; 53 (08) 1253-1261
    CrossrefPubMedGoogle Scholar
  • 25 Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol 2010; 99 (02) 217-225
    CrossrefPubMedGoogle Scholar
  • 26 Dunet V, Rossier C, Buck A, Stupp R, Prior JO. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med 2012; 53 (02) 207-214
    CrossrefPubMedGoogle Scholar
  • 27 Puranik AD, Boon M, Purandare N. et al. Utility of FET-PET in detecting high-grade gliomas presenting with equivocal MR imaging features. World J Nucl Med 2019; 18 (03) 266-272
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Lohmann P, Stavrinou P, Lipke K. et al. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging 2019; 46 (03) 591-602
    CrossrefPubMedGoogle Scholar
  • 29 Suchorska B, Jansen NL, Linn J. et al; German Glioma Network. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology 2015; 84 (07) 710-719
    CrossrefPubMedGoogle Scholar
  • 30 Harat M, Blok M, Miechowicz I, Wiatrowska I, Makarewicz K, Małkowski B. Safety and efficacy of irradiation boost based on 18F-FET-PET in patients with newly diagnosed glioblastoma. Clin Cancer Res 2022; 28 (14) 3011-3020
    CrossrefPubMedGoogle Scholar
  • 31 Laack NN, Pafundi D, Anderson SK. et al. Initial results of a phase 2 trial of 18F DOPA PET-guided dose-escalated radiation therapy for glioblastoma. Int J Radiat Oncol Biol Phys 2021; 110 (05) 1383-1395
    CrossrefPubMedGoogle Scholar
  • 32 Weller M, van den Bent M, Hopkins K. et al; European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014; 15 (09) e395-e403
    CrossrefPubMedGoogle Scholar
  • 33 Stupp R, Dietrich P-Y, Ostermann Kraljevic S. et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20 (05) 1375-1382
    CrossrefPubMedGoogle Scholar
  • 34 Habermeier A, Graf J, Sandhöfer BF, Boissel JP, Roesch F, Closs EI. System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET). Amino Acids 2015; 47 (02) 335-344
    CrossrefPubMedGoogle Scholar
  • 35 Mehrkens JH, Pöpperl G, Rachinger W. et al. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol 2008; 88 (01) 27-35
    CrossrefPubMedGoogle Scholar
  • 36 Pöpperl G, Götz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004; 31 (11) 1464-1470
    CrossrefPubMedGoogle Scholar
  • 37 Pöpperl G, Götz C, Rachinger W. et al. Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 2006; 33 (07) 792-800
    CrossrefPubMedGoogle Scholar
  • 38 Piroth MD, Pinkawa M, Holy R. et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011; 80 (01) 176-184
    CrossrefPubMedGoogle Scholar
  • 39 Van Mieghem E, Wozniak A, Geussens Y. et al. Defining pseudoprogression in glioblastoma multiforme. Eur J Neurol 2013; 20 (10) 1335-1341
    CrossrefPubMedGoogle Scholar
  • 40 Puranik AD, Rangarajan V, Dev ID. et al. Brain FET PET tumor-to-white mater ratio to differentiate recurrence from post-treatment changes in high-grade gliomas. J Neuroimaging 2021; 31 (06) 1211-1218
    CrossrefPubMedGoogle Scholar
  • 41 Contractor KB, Kenny LM, Stebbing J. et al. [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res 2009; 15 (17) 5503-5510
    CrossrefPubMedGoogle Scholar
  • 42 Li W, Ma L, Wang X, Sun J, Wang S, Hu X. (11)C-choline PET/CT tumor recurrence detection and survival prediction in post-treatment patients with high-grade gliomas. Tumour Biol 2014; 35 (12) 12353-12360
    CrossrefPubMedGoogle Scholar
  • 43 Bolcaen J, Acou M, Boterberg T. et al. 18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria. Nucl Med Commun 2017; 38 (03) 242-249
    CrossrefPubMedGoogle Scholar
  • 44 Choudhary G, Langen KJ, Galldiks N, McConathy J. Investigational PET tracers for high-grade gliomas. Q J Nucl Med Mol Imaging 2018; 62 (03) 281-294
    CrossrefPubMedGoogle Scholar
  • 45 Chen W, Delaloye S, Silverman DH. et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007; 25 (30) 4714-4721
    CrossrefPubMedGoogle Scholar
  • 46 Li Z, Yu Y, Zhang H, Xu G, Chen L. A meta-analysis comparing 18F-FLT PET with 18F-FDG PET for assessment of brain tumor recurrence. Nucl Med Commun 2015; 36 (07) 695-701
    CrossrefPubMedGoogle Scholar
  • 47 Bell C, Dowson N, Fay M. et al. Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation. Semin Nucl Med 2015; 45 (02) 136-150
    CrossrefPubMedGoogle Scholar
  • 48 Yamaguchi S, Hirata K, Toyonaga T. et al. Change in 18F-fluoromisonidazole PET is an early predictor of the prognosis in the patients with recurrent high-grade glioma receiving bevacizumab treatment. PLoS One 2016; 11 (12) e0167917
    CrossrefPubMedGoogle Scholar
  • 49 Windisch P, Röhrich M, Regnery S. et al. Fibroblast activation protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiother Oncol 2020; 150: 159-163
    CrossrefPubMedGoogle Scholar
  • 50 Huang R, Pu Y, Huang S. et al. FAPI-PET/CT in cancer imaging: a potential novel molecule of the century. Front Oncol 2022; 12: 854658
    CrossrefPubMedGoogle Scholar
  • 51 Wernicke AG, Edgar MA, Lavi E. et al. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med 2011; 135 (11) 1486-1489
    CrossrefPubMedGoogle Scholar
  • 52 Kunikowska J, Kuliński R, Muylle K, Koziara H, Królicki L. 68Ga-prostate-specific membrane antigen-11 PET/CT: a new imaging option for recurrent glioblastoma multiforme?. Clin Nucl Med 2020; 45 (01) 11-18
    CrossrefPubMedGoogle Scholar
  • 53 Marafi F, Sasikumar A, Fathallah W, Esmail A. 18F-PSMA 1007 brain PET/CT imaging in glioma recurrence. Clin Nucl Med 2020; 45 (01) e61-e62
    CrossrefPubMedGoogle Scholar